Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Commerce Hearing May 3 To Kick Off User Fee Reauthorization Debate

Executive Summary

Drug approval times will be one topic of interest at the House Energy & Commerce/Health Subcommittee's May 3 hearing kicking off the user fee reauthorization process, Commerce Committee Majority Counsel Brent Del Monte told the Food & Drug Law Institute conference April 18 in Washington, D.C.

You may also be interested in...



House Commerce Committee Medicare Rx Group Revisiting Risk Distribution

The House Energy & Commerce Medicare reform working group is revisiting the distribution of financial risk between private health plans and the federal government under a Medicare prescription drug plan.

House Commerce Committee Medicare Rx Group Revisiting Risk Distribution

The House Energy & Commerce Medicare reform working group is revisiting the distribution of financial risk between private health plans and the federal government under a Medicare prescription drug plan.

FTC Spadework For Waxman/Hatch Reform Includes Survey, Patent Forum

The Federal Trade Commission is working on a schedule to collect background material for Congress on Waxman/Hatch reform by the beginning of 2002.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel